HROW vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

HROW

53.2
AI Score
VS
HROW Wins

PCRX

45.6
AI Score

Investment Advisor Scores

HROW

53score
Recommendation
HOLD

PCRX

46score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HROW PCRX Winner
Revenue 214.16M 546.43M PCRX
Net Income -35.12M 36.09M PCRX
Net Margin -16.4% 6.6% PCRX
Operating Income -21.62M 33.44M PCRX
ROE -120.3% 5.1% PCRX
ROA -7.9% 3.0% PCRX
Total Assets 443.02M 1.20B PCRX
Cash 75.34M 246.96M PCRX
Current Ratio 2.29 4.68 PCRX
Free Cash Flow -28.42M 125.53M PCRX

Relative Price Performance (Last 90 Days)

HROW 1M: +4.0% · 3M: -24.4% PCRX 1M: +0.4% · 3M: +57.3%

Current Technical Phase

HROW

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 50.5 · Price: $29.37

PCRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (17.9% over 20 days), RSI 82

RSI (14): 81.6 · Price: $36.46

Fundamentals Snapshot

Metric HROW PCRX
Market Cap — —
Forward P/E 11.0 10.5
Trailing P/E — 39.2
Revenue (TTM) — —
Revenue Growth 0.4% 0.0%
Gross Margin 0.7% 0.8%
Operating Margin 0.1% 0.1%
EPS -0.99 0.93
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HROW is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.